Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Capecitabine clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention. Browse Capecitabine recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
760
Shown on this page
12
Current sort
Recently updated
Therapy scope
Capecitabine
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Capecitabine. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 313–324 of 760 matching trials for Capecitabine.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 1 Interventional

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

NCT02451553
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Bile Duct Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer
Interventions
Afatinib Dimaleate, Capecitabine, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

NCT01918644
View directory record Official record
Conditions
Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
stereotactic body radiation therapy, capecitabine, therapeutic conventional surgery, magnetic resonance imaging, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional

Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma

NCT02935309
View directory record Official record
Conditions
Rectal Cancer, Rectal Adenocarcinoma
Interventions
Lenvatinib, Capecitabine, External Radiation Therapy (XRT)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

NCT01360593
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Capecitabine, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
David A. Clump, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors

NCT01226732
View directory record Official record
Conditions
Metastatic or Unresectable Solid Tumor Malignancy
Interventions
Capecitabine, Hsp90 Inhibitor AUY 922
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Fort Myers, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

STAR Cape+BKM120 MBC With Brain Met

NCT02000882
View directory record Official record
Conditions
Brain Metastases, Breast Cancer, Metastatic Breast Cancer
Interventions
BKM120, capecitabine, Trastuzumab
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Multiple Locations, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NCT01945775
View directory record Official record
Conditions
Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
Interventions
talazoparib, Physician's-Choice
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
207
States / cities
Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Terminated Phase 2 Interventional Results available

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

NCT00321100
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
bevacizumab, cetuximab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 28, 2026, 10:46 AM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT03050814
View directory record Official record
Conditions
Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions
Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 28, 2026, 10:46 AM EDT
Not listed Phase 2 Interventional

Capecitabine in Metastatic Breast and GI Cancers

NCT02595320
View directory record Official record
Conditions
Breast Cancer, Gastrointestinal Cancer
Interventions
Capecitabine
Drug
Lead sponsor
Qamar Khan
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
15
States / cities
Fairway, Kansas • Garden City, Kansas • Great Bend, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 28, 2026, 10:46 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

NCT03111732
View directory record Official record
Conditions
Biliary Tract Neoplasms, Cholangiocarcinoma, Bile Duct Cancer, Liver Cancer, Gallbladder Cancer
Interventions
Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 28, 2026, 10:46 AM EDT
Terminated Phase 1 Interventional Results available

A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum

NCT01134601
View directory record Official record
Conditions
Non-Metastatic Adenocarcinoma of the Rectum
Interventions
Radiation Therapy, Capecitabine, AZD6244
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 28, 2026, 10:46 AM EDT

About this Capecitabine clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Capecitabine as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Capecitabine.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Capecitabine.